Abstract
Bacillus cereus is known as a serious bacterial pathogen in neutropenic patients. B. cereus is often resistant to beta-lactams, including penicillins and cephalosporins. We report a case of fatal pneumonia caused by B. cereus in a patient with newly diagnosed acute myeloid leukemia (AML) during remission induction therapy. Cefepime was started for febrile neutropenia (FN) initially and was switched to panipem/betamipron, when fulminant pneumonia supervened. The isolated strain was resistant not only to cefepime but also to panipenem/betamipron. This is the first report of fulminant infection caused by carbapenem-resistant B. cereus in a neutropenic patient. B. cereus should be kept in mind as a target of empirical treatment when neutropenic patients develop pneumonia.
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bacillaceae Infections / complications
-
Bacillaceae Infections / drug therapy
-
Bacillaceae Infections / microbiology*
-
Bacillus cereus / drug effects*
-
Bacillus cereus / isolation & purification
-
Carbapenems / pharmacology*
-
Carbapenems / therapeutic use
-
Fatal Outcome
-
Humans
-
Immunocompromised Host
-
Leukemia, Myeloid, Acute / complications*
-
Leukemia, Myeloid, Acute / diagnosis
-
Leukemia, Myeloid, Acute / drug therapy
-
Lung / diagnostic imaging
-
Male
-
Middle Aged
-
Neutropenia
-
Pneumonia, Bacterial / complications
-
Pneumonia, Bacterial / drug therapy
-
Pneumonia, Bacterial / microbiology*
-
Remission Induction
-
Tomography, X-Ray Computed
-
beta-Lactam Resistance*
Substances
-
Anti-Bacterial Agents
-
Antineoplastic Agents
-
Carbapenems